Clinical Trials & Research

Ose Immunotherapeutics will conduct a clinical trial involving up to 400 patients for an experimental COVID-19 vaccine it hopes can further help fight the global pandemic. This vaccine wouldn’t be available until 2022, assuming the investigational product produces positive results in clinical trials. Different Approach While most treatments to date emphasize “neutralizing antibodies” to beat SARS-CoV-2
0 Comments
The National Institutes of Health has awarded the Oklahoma Medical Research Foundation $3.7 million to continue research on Sjögren’s syndrome, an autoimmune disease. OMRF scientist Christopher Lessard, Ph.D., received a five-year grant to identify genes associated with the disease. The work will aid in the development of strategies to diagnose and treat the condition. In
0 Comments
Calico Life Sciences LLC was founded in 2013 as a Google-backed venture with the goal of combating aging and associated disease. Described by Larry Page, co-founder of Google, at the time as a venture targeting “health, well-being, and longevity,” the name of the company was actually an acronym for “California Life Company.” Several years later, the company now
0 Comments
A global contract research organization (CRO) based in Ireland has won a major U.S. government contract associated with the war on COVID-19.  ICON Plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device industries and government and public health organizations, has been re-selected by the Biomedical
0 Comments
SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) – AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis (GPP),
0 Comments
COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into the Phase 2 clinical trial collaboration of its lead investigational drug, lasofoxifene,
0 Comments
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) – Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today the topline results from its Hamster Challenge Study. The available results show that all hamsters that received two oral doses of COVID-19 vaccine candidate showed no systemic
0 Comments
PARIS and LEXINGTON, MASS. – October 15, 2020 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease. Preclinical evaluation of MRT5500, importantly, demonstrated a
0 Comments
KENILWORTH, N.J.–(BUSINESS WIRE) October 16, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer clinical development program evaluating Keytruda, Merck’s anti-PD-1 therapy: Keytruda in combination with chemotherapy (KEYNOTE-021 [Cohort G]) and Keytruda in combination with quavonlimab (MK-1308),
0 Comments
October 16, 2020 — The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 Electromagnetic energy in the brain enables brain matter to create our consciousness and our ability to be aware and think, according to a new theory developed by Professor Johnjoe McFadden from the University of Surrey. Publishing his theory in the eminent Oxford University Press journal Neuroscience of Consciousness,
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 A highly effective drug therapy is urgently required to combat coronavirus disease 2019 (COVID-19). The authors of this article have developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 An international group of researchers believe there is enough evidence that anti-malarial drugs could be repurposed to treat COVID-19 and that they should be assessed for efficacy in clinical trials. The review article, published online in Trends in Parasitology, outlines the evidence for the antiviral and anti-inflammatory properties
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continues to cause human infection and mortality worldwide. Currently, there are no specific viral protein-targeted therapeutics available. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 Patients with thyroid dysfunction are routinely treated with drugs to regulate the hormone imbalance. The effect of these drugs is clinically evaluated by means of blood tests. A team led by Michael Krebs from MedUni Vienna’s Division of Endocrinology and Metabolism has now conducted a study to test
0 Comments
Reviewed by Emily Henderson, B.Sc.Oct 20 2020 Older adults with higher physical activity and lower sitting time have better overall physical and mental health, according to a new study from the American Cancer Society (ACS). The study, appearing in the journal, CANCER, suggests that higher amounts of regular moderate- to vigorous-intensity physical activity (MVPA) and
0 Comments